🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Lapaquistat acetate and fenofibrate

    Takeda

    Hyperlipidemias

    phase 2 small molecule completed

    1 trial

  2. Lenalidomide

    Takeda

    Myeloma, Multiple

    phase 2 small molecule active

    1 trial

  3. Leuprorelin

    Takeda

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  4. Leuprorelin (GF)

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  5. Levothyroxine sodium new formulation

    Takeda

    Hypothyroidism

    phase 2 small molecule completed

    1 trial

  6. Lifitegrast

    Takeda

    Dry Eye

    phase 2 small molecule completed

    1 trial

  7. Lifitegrast

    Takeda

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  8. Lubiprostone

    Takeda

    Irritable Bowel Syndrome

    phase 2 small molecule terminated

    3 trials

  9. MCC-135

    Takeda

    Congestive Heart Failure

    phase 2 small molecule completed

    1 trial

  10. MLN0264

    Takeda

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  11. MLN0264

    Takeda

    Adenocarcinoma of the Stomach

    phase 2 small molecule terminated

    1 trial

  12. MLN1202

    Takeda

    Atherosclerotic Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  13. MLN1202 Placebo

    Takeda

    Diabetic Nephropathy

    phase 2 small molecule terminated

    1 trial

  14. Maribavir

    Takeda

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  15. Melphalan

    Takeda

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  16. Methylphenidate + SPD503 (Guanfacine hydrochloride)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  17. Mezagitamab

    Takeda

    Relapsed/Refractory

    phase 2 small molecule completed

    1 trial

  18. Mifamurtide

    Takeda

    Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  19. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial

  20. NDI-034858

    Takeda

    Psoriatic Arthritis

    phase 2 small molecule completed

    1 trial

  21. NDI-034858 study drug

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  22. NPS 1776 (800 mg)

    Takeda

    Migraine Headache

    phase 2 small molecule completed

    1 trial

  23. NPSP795

    Takeda

    Autosomal Dominant Hypocalcemia (ADH)

    phase 2 small molecule completed

    1 trial

  24. Namilumab

    Takeda

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources